110 related articles for article (PubMed ID: 16328042)
1. Inhibition of proliferative and invasive capacities of breast cancer cells by arginine-glycine-aspartic acid peptide in vitro.
Yang W; Meng L; Wang H; Chen R; Wang R; Ma X; Xu G; Zhou J; Wang S; Lu Y; Ma D
Oncol Rep; 2006 Jan; 15(1):113-7. PubMed ID: 16328042
[TBL] [Abstract][Full Text] [Related]
2. Dual function of RGD-modified VEGI-192 for breast cancer treatment.
Wu J; Jiang Y; Yang W; He Z; Meng S; Zhang Q; Lin M; Zhang H; Li W; Yang Y; Jia Y; Qian L; Lu D; Cai W; Luo G; Wang Y; Zhu X; Li M
Bioconjug Chem; 2012 Apr; 23(4):796-804. PubMed ID: 22455451
[TBL] [Abstract][Full Text] [Related]
3. Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha(v)beta3 and alpha(v)beta5 integrins.
Sung V; Stubbs JT; Fisher L; Aaron AD; Thompson EW
J Cell Physiol; 1998 Sep; 176(3):482-94. PubMed ID: 9699501
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of antimicrobial peptides containing CisoDGRC in CD13 negative breast cancer cells.
Hou L; Zhao X; Wang P; Ning Q; Meng M; Liu C
PLoS One; 2013; 8(1):e53491. PubMed ID: 23326440
[TBL] [Abstract][Full Text] [Related]
5. Targeting integrins with RGD-conjugated gold nanoparticles in radiotherapy decreases the invasive activity of breast cancer cells.
Wu PH; Onodera Y; Ichikawa Y; Rankin EB; Giaccia AJ; Watanabe Y; Qian W; Hashimoto T; Shirato H; Nam JM
Int J Nanomedicine; 2017; 12():5069-5085. PubMed ID: 28860745
[TBL] [Abstract][Full Text] [Related]
6. Proteomics analysis of a novel compound: cyclic RGD in breast carcinoma cell line MCF-7.
Juan HF; Wang IH; Huang TC; Li JJ; Chen ST; Huang HC
Proteomics; 2006 May; 6(10):2991-3000. PubMed ID: 16619296
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery.
Chen X; Plasencia C; Hou Y; Neamati N
J Med Chem; 2005 Feb; 48(4):1098-106. PubMed ID: 15715477
[TBL] [Abstract][Full Text] [Related]
8. Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy.
DeNardo SJ; Burke PA; Leigh BR; O'Donnell RT; Miers LA; Kroger LA; Goodman SL; Matzku S; Jonczyk A; Lamborn KR; DeNardo GL
Cancer Biother Radiopharm; 2000 Feb; 15(1):71-9. PubMed ID: 10740655
[TBL] [Abstract][Full Text] [Related]
9. Alpha v integrins as receptors for tumor targeting by circulating ligands.
Pasqualini R; Koivunen E; Ruoslahti E
Nat Biotechnol; 1997 Jun; 15(6):542-6. PubMed ID: 9181576
[TBL] [Abstract][Full Text] [Related]
10. Potent antitumor effect elicited by RGD-mda-7, an mda-7/IL-24 mutant, via targeting the integrin receptor of tumor cells.
Zhang BF; Liu JJ; Pei DS; Yang ZX; Di JH; Chen FF; Li HZ; Xu W; Wu YP; Zheng JN
Cancer Biother Radiopharm; 2011 Oct; 26(5):647-55. PubMed ID: 21902545
[TBL] [Abstract][Full Text] [Related]
11. Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature.
Mukhopadhyay S; Barnés CM; Haskel A; Short SM; Barnes KR; Lippard SJ
Bioconjug Chem; 2008 Jan; 19(1):39-49. PubMed ID: 17845003
[TBL] [Abstract][Full Text] [Related]
12. Anticancer activity of targeted proapoptotic peptides.
Capello A; Krenning EP; Bernard BF; Breeman WA; Erion JL; de Jong M
J Nucl Med; 2006 Jan; 47(1):122-9. PubMed ID: 16391196
[TBL] [Abstract][Full Text] [Related]
13. Designed synthetic analogs of the α-helical peptide temporin-La with improved antitumor efficacies via charge modification and incorporation of the integrin αvβ3 homing domain.
Diao Y; Han W; Zhao H; Zhu S; Liu X; Feng X; Gu J; Yao C; Liu S; Sun C; Pan F
J Pept Sci; 2012 Jul; 18(7):476-86. PubMed ID: 22641352
[TBL] [Abstract][Full Text] [Related]
14. Expression, purification, and characterization of RGD-mda-7, a His-tagged mda-7/IL-24 mutant protein.
Liu JJ; Zhang BF; Yin XX; Pei DS; Yang ZX; Di JH; Chen FF; Li HZ; Xu W; Wu YP; Zheng JN
J Immunoassay Immunochem; 2012; 33(4):352-68. PubMed ID: 22963485
[TBL] [Abstract][Full Text] [Related]
15. The PHSCN dendrimer as a more potent inhibitor of human breast cancer cell invasion, extravasation, and lung colony formation.
Yao H; Veine DM; Fay KS; Staszewski ED; Zeng ZZ; Livant DL
Breast Cancer Res Treat; 2011 Jan; 125(2):363-75. PubMed ID: 20300829
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of Modified RGD-Based Peptides and Their in vitro Activity.
Hamdan F; Bigdeli Z; Asghari SM; Sadremomtaz A; Balalaie S
ChemMedChem; 2019 Jan; 14(2):282-288. PubMed ID: 30506622
[TBL] [Abstract][Full Text] [Related]
17. Arginine-glycine-aspartic acid (RGD)-containing peptides inhibit the force production of mouse papillary muscle bundles via alpha 5 beta 1 integrin.
Sarin V; Gaffin RD; Meininger GA; Muthuchamy M
J Physiol; 2005 Apr; 564(Pt 2):603-17. PubMed ID: 15718258
[TBL] [Abstract][Full Text] [Related]
18. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo.
Zitzmann S; Ehemann V; Schwab M
Cancer Res; 2002 Sep; 62(18):5139-43. PubMed ID: 12234975
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.
Basu GD; Pathangey LB; Tinder TL; Gendler SJ; Mukherjee P
Breast Cancer Res; 2005; 7(4):R422-35. PubMed ID: 15987447
[TBL] [Abstract][Full Text] [Related]
20. Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions.
Xuan JW; Hota C; Shigeyama Y; D'Errico JA; Somerman MJ; Chambers AF
J Cell Biochem; 1995 Apr; 57(4):680-90. PubMed ID: 7542253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
